SYNCOM FORMULATIONS (INDIA) LTD.-$

Syncom Formulations India Ltd has announced a trading window closure for its shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 1, 2026, until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. During this period, promoters, directors, KMPs, designated employees, and their immediate relatives are advised not to trade in the company's shares. The company will inform the stock exchanges about the board meeting date for approving these financial results in due course and will update the designated depository (CDSL) accordingly.

Syncom Formulations India Ltd has released its audited financial results for the year ended March 31, 2026. The company reported revenue from operations of ₹486.57 million and a profit of ₹76.01 million for the year. The results were approved by the Audit Committee and Board of Directors in a meeting held on May 22, 2026. The auditors' report is unmodified, and the company is in the process of filing the results in XBRL format and publishing them in newspapers.

Syncom Formulations India Ltd. has released its standalone and consolidated audited financial results for the year ended March 31, 2026. Key figures include revenue from operations of ₹486.57 million and a profit of ₹76.01 million for the period. The board meeting approving these results took place on May 22, 2026. Auditors' report is unmodified, requiring no further comments from the company. The results will be published in English and Marathi newspapers and filed in XBRL format.

Syncom Formulations India Ltd has scheduled a Board of Directors meeting on May 22, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The board will also review the audit report and financial statements. The meeting will be held at the company's corporate office in Indore.

Syncom Formulations India Ltd has successfully completed the purchase of a commercial property, specifically the entire 7th Floor, Trade Star, Andheri-Kurla Road, Andheri (E), Mumbai, for a total consideration of ₹57.26 Crore. The property was acquired from HDFC Bank Ltd, and the company has made the full and final payment.

Syncom Formulations India Ltd. has received the Yearly Disclosure for the financial year ended on 31st March, 2026 from its promoters - Shri Kedarmal Shankarlal Bankda and Shri Vijay Shankarlal Bankda, along with their Persons Acting in Concert (PAC). The disclosure, as per Regulation 31(4) of SEBI (SAST) Regulations, 2011, has been submitted to the Audit Committee of the Company, BSE Limited, and National Stock Exchange of India Limited. The promoters have declared no encumbrance in the securities of Syncom Formulations (India) Limited, other than those already disclosed during the Financial Year ended on 31st March, 2026.

Syncom Formulations India Ltd. has announced the closure of its trading window from 1st April 2026 till completion of 48 hours after the declaration of Audited Standalone & Consolidated Financial Results for the Quarter and Year ended on 31st March 2026. This decision is in accordance with SEBI (Prohibition of Insider Trading) Regulation, 2015 and BSE circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019. The company is required to give prior intimation to the designated depository appointed by the company, i.e. CDSL, at least 2 trading days prior to the commencement of the trading window. All Promoter and Promoter group, Directors, KMP’s, Designated Persons/Employees, Connected Persons, Fiduciaries of the Company and their immediate relatives are advised not to deal in the shares of the Company either directly or indirectly during the aforesaid period. The date of the meeting of the Board of Directors to approve the Audited Standalone & Consolidated Financial Results for the Quarter and Year ended on 31st March 2026 will be informed in due course.

Syncom Formulations India Ltd. has submitted its unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2025. The results were approved in a Board meeting on 12th February, 2026. The company will file the results in XBRL format and publish them in English and Marathi newspapers.

Syncom Formulations India Ltd. has announced that its Board of Directors will meet on February 12, 2026, to consider and approve the Standalone and Consolidated unaudited Financial Results for the Quarter and Nine Months ended 31 December, 2025. The meeting will also take on record the Standalone and Consolidated Limited Review Report by Auditors for the unaudited Financial Results. Additionally, the Board will consider other incidental matters.

Syncom Formulations India Ltd. has received a demand notice from the Department of Revenue under GST, raising a penalty of Rs. 1.42 crore for ineligible Input Tax Credits. The company had previously applied for an appeal, which was rejected. The company will further move for an appeal to the relevant authority and remains committed to ensuring optimum compliance with all applicable laws.